Pharmaron Beijing Co., Ltd.*
3759
2020 6 30
6 30
2020 2019
%
2,193,167 1,636,513 34.0
794,400 522,425 52.1
478,960 161,323 196.9
431,608 163,031 164.7
617,948 252,315 144.9
2,193.2 2019 6
30 556.7 34.0%
479.0 2019
6 30 196.9%
617.9
2019 6 30 144.9%
2020 6 30
2020 6
30 2019
1
2020 6 30
6 30
2020 2019
4 2,193,167 1,636,513
(1,398,767) (1,114,088)
794,400 522,425
5 202,817 21,263
5 (40,442) (12,606)
(40,422) (28,766)
(303,525) (241,463)
(43,104) (26,687)
(3,215) 724
(13,386) (42,399)
(20,824) (5,798)
6 532,299 186,693
7 (65,664) (30,012)
466,635 156,681
478,960 161,323
(12,325) (4,642)
466,635 156,681
9 0.6053 0.2500
9 0.6045 0.2500
2
2020 6 30
6 30
2020 2019
466,635 156,681
(30,421) (1,707)
(30,421) (1,707)
(30,421) (1,707)
436,214 154,974
448,509 159,656
(12,295) (4,682)
436,214 154,974
3
2020 6 30
2020 2019
6 30 12 31
3,116,530 2,973,354
530,393 498,989
43,421 46,013
364,225 203,286
85,706 35,352
300,820 131,246
160,708 59,054
7,096 6,372
91,471 36,921
4,700,370 3,990,587
129,627 97,050
101,665 60,347
10 967,152 857,069
114,934 89,105
189,413 197,576
727,472 169,762
– 13,689
7,276 17,634
3,045,927 4,442,218
5,283,466 5,944,450
24,681 300,654
11 164,164 117,978
627,471 486,702
371,400 271,547
77,075 64,150
14,164 –
46,206 28,649
1,325,161 1,269,680
3,958,305 4,674,770
8,658,675 8,665,357
4
2020 2019
6 30 12 31
127,731 543,791
50,633 40,782
113,918 111,606
157,457 131,160
449,739 827,339
8,208,936 7,838,018
12 794,387 794,387
(72,170) (72,781)
7,411,643 7,045,457
8,133,860 7,767,063
75,076 70,955
8,208,936 7,838,018
5
2020 6 30
1.
2004 7 1
2019 1
28 300759.SZ 2019 11 28
3759.HK
6 1 8
CMC
2.1
2020 6 30
34
2019 12 31
2.2
2019 12 31
3
9
39
7
16
1
8
6
(a) 3
2020 1 1
(b) 9 39 7
9
39
(c) 16
(i)
(ii) 2021 6 30
(iii) 2020 6
30
(d) 1 8
7
3.
DMPK/ADME
CMC
2020 6 30
CMC
1,433,721 506,460 242,549 10,437 2,193,167
589,491 145,794 52,893 6,222 794,400
202,817
(40,442)
(40,422)
(303,525)
(43,104)
(3,215)
(13,386)
(20,824)
532,299
8
2019 6 30
CMC
1,059,856 376,885 190,215 9,557 1,636,513
395,361 77,486 43,867 5,711 522,425
21,263
(12,606)
(28,766)
(241,463)
(26,687)
724
(42,399)
(5,798)
186,693
(a)
6 30
2020 2019
1,389,926 966,709
454,454 392,795
66,860 74,004
256,632 191,482
25,295 11,523
2,193,167 1,636,513
9
(b)
2020 2019
6 30 12 31
3,801,367 3,200,346
329,903 319,903
401,296 404,912
4,532,566 3,925,161
4.
6 30
2020 2019
2,182,730 1,626,956
10,437 9,557
2,193,167 1,636,513
(a)
6 30
2020 2019
1,433,721 1,059,856
CMC 506,460 376,885
242,549 190,215
2,182,730 1,626,956
1,172,809 857,882
1,009,921 769,074
2,182,730 1,626,956
10
(b)
FTE FFS
FTE
15
FTE
FFS
5.
6 30
2020 2019
43,143 1,513
5,159 4,546
11,428 1,254
59,730 7,313
3,231 1,863
100,837 1,054
15,722 450
23,123 10,363
174 220
143,087 13,950
202,817 21,263
(390) (206)
(35,303) (10,479)
(4,749) (1,921)
(40,442) (12,606)
11
6.
6 30
2020 2019
167,654 148,216
34,307 29,717
411 403
3,179 1,378
727,978 571,209
160,095 169,963
34,570 –
(23,123) (10,363)
(15,722) (450)
(100,837) (1,054)
2,162 826
3,215 (724)
35,303 10,479
1,740 1,190
*
7.
6 30
2020 2019
64,707 22,143
957 7,869
65,664 30,012
8.
2020 5 28 2019 A
H 2019 12 31 0.15
119,158,000 A 611,000
2020 7
2019 6 30
12
9.
6 30
2020 2019
478,960 161,323
(611) –
478,349 161,323
611 –
478,960 161,323
6 30
2020 2019
790,310,075 645,355,242
2,000,880 –
792,310,955 645,355,242
10.
2020 2019
6 30 12 31
1 960,095 849,691
1 2 7,057 7,378
967,152 857,069
412,000 2019 12 31
13
11.
2020 2019
6 30 12 31
160,994 114,897
3,170 3,081
164,164 117,978
528,000 2019 12 31 4,000
30
12.
2020 2019
6 30 12 31
794,387 794,387
2019 12 31 2020 1 1 794,387,462 794,387
2020 6 30 794,387,462 794,387
14
DMPK/ADME
CMC
NMPA FDA OECD GLP
GMP
&
2020 6 30
8,000 9,113
15
2020
2020
2,193.2 34.0%
479.0
196.9% 617.9
144.9%
CMC
2020 190
90%
2020
28 IND
20 2020 CMC
463 292
134 35 2
DMPK/ADME
IND
16
CMC
CMC
CMC 2020
1
DMPK/ADME
1,433.7 35.3%
41.1% 3.8%
2020 6 30
4,926 2019 12 31 625
17
2 CMC
CMC
CMC
CMC 2020
2020
CMC 506.5
34.4% 28.8% 8.2%
CMC
CMC
CMC
463 292
134 35 2
200
800
CMC
CMC CMC
2020 6 30 CMC 1,646 2019 12 31
102
3
SMO
2020
242.5
27.5% 21.8% 1.3%
18
2020 6 30
SMO
SMO
2020 6 30 1,480
2019 12 31 924 2020 6 30
794.4 2019 6 30
522.4 2019 6 30 31.9% 36.2%
2019 6 30 395.4
589.5 2019 6 30
37.3% 41.1%
CMC 2019 6 30 77.5
145.8 CMC CMC
2019 6 30 20.6% 28.8%
CMC
2019 6 30 43.9
52.9 2019 6 30
23.1% 21.8% 1.3%
19
202.8 2019 6 30
853.8% 181.6 (1)
Zentalis Pharmaceuticals, Inc. Zentalis 2020 4 3
ZNTL Zentalis 2020 6 30
Zentalis
100.8 (2) 41.6 (3)
10.8 (4) 15.3
(5)2020 6
23.1 2019 6
10.4
40.4 2019 6 30
40.5% 11.7
303.5 2019 6 30
241.5
2019 6 30 14.8%
13.8%
43.1 2019 6 30
61.5% 16.4
13.4 2019 6 30
68.4% 29.0
20
65.7 2019 6 30
118.8% 35.7
479.0
2019 6 30 161.3 196.9%
(i)
(ii)
(iii)
21
2020 2019
6 30 6 30
478,960 161,323
28,488 –
(2,712) (1,563)
30,008 8,907
534,744 168,667
(103,136) (5,636)
431,608 163,031
617.9
2019 6 30 365.6 144.9%
2,032.4
2019 6 30 1,530.4 304.8%
(1)
1,279.7
(2) CMC
393.7 (3)
340.2
743.1
22
2020 6 30
3,045.9
617.9
2020 6 30 5,283.5 2019 12
31 5,944.5 1,325.2 2019
12 31 1,269.7 2020 6 30
4.0 2019 12 31 4.7
2020 6 30 152.4
24.7 127.7
2020 6 30 17.8% 2019
12 31 21.1%
2020 6 30 588.4
2019 12 31 1,333.2
80.7 2019 12 31 81.7
2020 6 30
7.3 2019 12 31 17.6
2020 6 30
23
2020 1 20
14A
2020 1 20 2020 2 6
20%
2019 12 31
20% 2020 6 30 68%
AccuGen
2019 31
12 AccuGen 50%
2020 4 9
AccuGen 50% AccuGen
CMC 2020
24
1
(1)
25
GLP/GMP
GMP GMP
(2) DMPK/ADME
DMPK/ADME
DMPK/ADME
AMS
(3) IND
IND CMC
IND
IND
2
26
IND
3
4
2020 190
90%
27
5
30
10
100 3 14
1,381
2020 6 30
8,000
28
2020
1.
(1)
2019 944
2014 2019 10.3%
2023 1,470
2019
108 2023 299 2
(2)
2019 130
37.0% 2023
191 2019 2023
10.1%
42.5% 2019
15
51.7% 2023
42
59%
29
(3)
2019 CMO
303 18.4% 2023
CMO 518 2019 2023
14.3% 2019 CMO
30 CMO 9.8% 2023
CMO 85 CMO
15.7% CMO 21.2%
(4)
2019
406 2024 602
8.2%
36 8.9%
2024
120 27.0%
8.2%
2.
30
2020
(1)
2020
2020
CMC
(2)
DNA
31
(3)
2020
(4)
(5)
(6)
32
3.
(1)
(2)
33
(3)
(4)
FDA NMPA
34
(5)
2015
(6)
(7)
35
(8)
CMC
(9)
(10)
36
2020 6 30
H
4,522.7 2020 6 30 3,637.4
2019 11 14
2020 6 30
2020
2020 6 30
6 30
(1)
30.0% 1,356.8 375.0 981.8 2021 12 31
19.5% 881.9 244.6 637.3 2021 12 31
4.5% 203.5 62.1 141.4 2021 12 31
37
6.0% 271.4 68.3 203.1 2021 12 31
10.0% 452.3 – 452.3 2021 12 31
20.0% 904.5 – 904.5 2022 12 31
15.0% 678.4 58.0 620.4 2022 12 31
CRO CMO 15.0% 678.4 – 678.4 2022 12 31
10.0% 452.3 452.3 – 2020 6 30
– 4,522.7 885.3 3,637.4 –
38
2020 6 30 9,113 2019 12 31
7,393
2019 2020 5 28 2019
10 1.50
119.2 A 0.6
2020 7
10
A.2.1
39
3.21
14
2410
(www.hkexnews.hk) (www.pharmaron.
com) 2020
AMS
A 1.00
CMC
40
CMO
CNS
2018 2 7
55.56%
CRO
DMPK/ADME
FDA
GLP (Good Laboratory Practice)
GMP
H
1.00
IND
2012
7 19
NMPA
41
OECD
2015 1 12
2017 1 3
2008 7 16
2020 6 30
SMO
%
2020 8 26
*
42